BRANMOOR
THURSDAY · 14 MAY 2026

FDA Recall D-0893-2023

The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · La Vergne, TN

Class I — life-threatening Terminated 398 days on record

Highest impact — Class I recall — FDA determination of strong likelihood of serious adverse health consequence or death.

Product

ZIPRASIDONE HYDROCHLORIDE CAPSULES 20 mg, Unit Dose Carton 40 Capsules, Rx only, Mfd. By: Dr. Reddy's Laboratories Limited Bachupally-500 090 India, Distributed by: Major Pharmaceuticals Livonia, MI 48152 USA, NDC 0904-6269-08

Lot / code: Lot: T04769 Exp. 2024/12

Quantity: unknown

Reason for recall

Labeling: Label Mix-up: Unit Dose cartons labeled as Ziprasidone Hydrochloride Capsules, 20 mg were found to contain blister packages labeled as and containing Dronabinol Capsules, USP, 2.5 mg.

Recall record

Recall number
D-0893-2023
Classification
Class I
Status
Terminated
Voluntary or mandated
Voluntary: Firm initiated
Firm notification
Letter
Distribution
Nationwide in the USA
Recall initiated
2023-05-31
Classified by FDA Center
2023-07-05
FDA published
2023-06-28
Terminated
2024-07-02
Recalling firm
The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories
Firm location
La Vergne, TN

Drug identification

Brand name(s)
ZIPRASIDONE
Generic name(s)
ZIPRASIDONE
Manufacturer(s)
Major Pharmaceuticals
NDC(s)
0904-6269, 0904-6270, 0904-6271, 0904-6272
Route(s)
ORAL

‹ All recalls